Dupixent Label Updated With Phase III Trial Data for Atopic Dermatitis With Uncontrolled Hand and Foot Involvement
Data from the Phase III LIBERTY-AD-HAFT trial show 40% of patients with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement who were administered Dupixent achieved clear or almost clear skin on their hands and feet.
Image credit: lial88 | stock.adobe.com
The FDA has updated the label for Regeneron Pharmaceuticals, Inc’s Dupixent (dupilumab) to include efficacy and safety data for patients 12 years of age and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement. Dupixent is an interleukin (IL)-4 receptor alpha antagonist that has been approved for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The drug also has approved indications for asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.
“We rely heavily on our hands and feet throughout the day, making atopic dermatitis particularly disruptive for patients who experience constant itch and painful cracking and bleeding skin lesions on these critical areas of the body,” principal inventor of Dupixent George D. Yancopoulos, MD, PhD, board co-Chair, president, and chief scientific officer at Regeneron, said in a press release. “Dupixent has been used to treat hundreds of thousands of patients with moderate-to-severe atopic dermatitis around the world since its initial U.S. approval in 2017, and we are pleased that Dupixent is now the first biologic with data in the label supporting its use in this particularly challenging subset of the disease.”
The updated data come from the Phase III LIBERTY-AD-HAFT trial, which was the first to analyze a biologic drug in this difficult-to-treat patient population, according to Regeneron. Dupixent’s label was also updated in the European Union, with regulatory submissions ongoing in other countries.
The double-blind, placebo-controlled study enrolled 133 adolescents and adults with moderate-to-severe atopic hand and foot dermatitis who previously showed an inadequate response or intolerance to topical corticosteroids. Patients in the treatment cohort were administered Dupixent (n=67) every two weeks at a dose of 300 mg in adults, 200 mg in adolescents, or 300 mg based on body weight to compare safety and efficacy data with a placebo cohort (n=66). After 16 weeks, 40% of patients administered Dupixent achieved clear or almost clear skin on their hands and feet vs. 17% of those in the placebo cohort (p≤0.01), which was the trial’s primary endpoint.
Further, 52% of patients administered Dupixent experienced a clinically meaningful reduction in itch on hands and feet vs. 14% with placebo (p<0.0001), which was the trial’s key secondary endpoint; 69% of patients administered Dupixent had an average decrease in signs of hand and foot lesions from baseline vs. 31% with placebo (p<0.0001); patients administered Dupixent showed a 75% average improvement in hand eczema disease severity from baseline vs. 40% with placebo (p<0.0001); and patients administered Dupixent experienced significant improvements in measures of hand and foot skin pain, sleep, and hand eczema-related quality of life.
In terms of safety, patients in the Dupixent cohort showed similar safety outcomes to the known profile of Dupixent for atopic dermatitis, with overall rates of adverse events at 66% in the Dupixent group compared with 74% for placebo.
“Atopic hand and foot dermatitis can extensively disrupt the lives of patients, given the intense itch and painful skin lesions it causes on essential body areas,” principal trial investigator Eric L. Simpson, MD, Frances J. Storrs Professor of Medical Dermatology at the Oregon Health and Science University, said in the release. “In this trial, Dupixent significantly improved disease signs, symptoms and quality of life measures for this particularly difficult-to-treat subset of atopic dermatitis patients, with itch improvement seen as early as one week after the first dose. While the efficacy and safety profile of Dupixent is well-established for atopic dermatitis more broadly, these positive results are the first demonstrating the impact on specific and heavily used areas of the body.”
Reference
Dupixent® (Dupilumab) U.S. Label Updated With Data Further Supporting Use in Atopic Dermatitis With Moderate-To-Severe Hand and Foot Involvement. Regeneron. News release. January 16, 2024. Accessed January 16, 2024. https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-us-label-updated-data-further-supporting-use
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
The Importance of Real-World Evidence in Medical Research and Drug Development
February 18th 2025The ongoing evolution of real-world evidence from a novel concept to a cornerstone of modern medical research signifies its growing importance and vast potential to improve personalized medicine, overall healthcare outcomes, and eventually democratization of scientific facts by general accessibility.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
